Symposium - European Medical Journal

This site is intended for healthcare professionals

Continue

Symposiums

Diabetes
6 Mins
14 Oct 2020

Kidney Disease: Improving Global Outcomes (KDIGO) New Guideline for Diabetes Management in Chronic Kidney Disease: A Meet-the-Expert Session

Diabetes is a chronic, metabolic disease characterised by elevated blood glucose levels, which over time leads to serious damage to the heart…
EMJ Hematology 8 [Supplement 5] 2020 Feature Image
Hematology
12 Mins
24 Sep 2020

The Impact of Sickle Cell Disease: Updates in Therapeutics, Treatment, Management, and Future Directions

Although VOC are the hallmark of SCD, a lack of VOC events does not prevent chronic multi-organ damage. Patients with sickle cell anaemia (SCA)…
EMJ Oncology 8 [Supplement 2] 2020
Oncology
8 Mins
26 Aug 2020

Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer

MONARCH 2 was a global, randomised, double-blind, Phase III study of abemaciclib or placebo in combination with fulvestrant in premenopausal…
Allergy & Immunology
12 Mins
10 Aug 2020

Type 2 Inflammation in Atopic Dermatitis and Beyond: Shared Pathophysiology and Clinical Management

Prof Maurer explored the common role of type 2 inflammation in the shared pathophysiology and epidemiology of AD and other type 2 inflammatory diseases…
Gastroenterology
11 Mins
4 Aug 2020

Nutritional Management of Paediatric Crohn’s Disease

For many people with Crohn’s disease (CD), onset occurs in childhood or adolescence. Treatment for CD has moved from predominantly surgical to…
Doing More for Patients with Immune Thrombocytopenia
Hematology
9 Mins
30 Jul 2020

Doing More for Patients with Immune Thrombocytopenia: Putting New Recommendations into Practice

The American Society of Hematology (ASH) guidelines and the International Consensus Report (ICR) recommendations were first published in 2010 and 2011…
hematology 8.1 featured image
Hematology
10 Mins
30 Jul 2020

Outcomes for Patients with High-Risk Acute Myeloid Leukaemia: Can We Move from Months to Years?

This symposium focussed on the recognition of, and treatment options for, high-risk AML. Prof Cluzeau considered universal or targeted treatment…
AGILE: Phase III, Double-Blind, Randomised, Placebo-Controlled Study
Hematology
2 Mins
30 Jul 2020

AGILE: Phase III, Double-Blind, Randomised, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukaemia and an IDH1 Mutation

Isocitrate dehydrogenase 1 (IDH1) is a metabolic enzyme which catalyses the oxidative decarboxylation of isocitrate to α-ketoglutarate…
We’ve noticed you’re accessing
from North/South America.